208 related articles for article (PubMed ID: 34919974)
1. Concordance of Anyplex™ II HPV HR assays with reference HPV assays in cervical cancer screening: Systematic review.
Biazin H
J Virol Methods; 2022 Mar; 301():114435. PubMed ID: 34919974
[TBL] [Abstract][Full Text] [Related]
2. Clinical validation of Anyplex™ II HPV HR Detection according to the guidelines for HPV test requirements for cervical cancer screening.
Hesselink AT; Sahli R; Berkhof J; Snijders PJ; van der Salm ML; Agard D; Bleeker MC; Heideman DA
J Clin Virol; 2016 Mar; 76():36-9. PubMed ID: 26809131
[TBL] [Abstract][Full Text] [Related]
3. The Abbott RealTime High Risk HPV test is a clinically validated human papillomavirus assay for triage in the referral population and use in primary cervical cancer screening in women 30 years and older: a review of validation studies.
Poljak M; Oštrbenk A
Acta Dermatovenerol Alp Pannonica Adriat; 2013; 22(2):43-7. PubMed ID: 23836358
[TBL] [Abstract][Full Text] [Related]
4. 2020 list of human papillomavirus assays suitable for primary cervical cancer screening.
Arbyn M; Simon M; Peeters E; Xu L; Meijer CJLM; Berkhof J; Cuschieri K; Bonde J; Ostrbenk Vanlencak A; Zhao FH; Rezhake R; Gultekin M; Dillner J; de Sanjosé S; Canfell K; Hillemanns P; Almonte M; Wentzensen N; Poljak M
Clin Microbiol Infect; 2021 Aug; 27(8):1083-1095. PubMed ID: 33975008
[TBL] [Abstract][Full Text] [Related]
5. Clinical and Analytical Evaluation of the Anyplex II HPV HR Detection Assay within the VALGENT-3 Framework.
Oštrbenk A; Xu L; Arbyn M; Poljak M
J Clin Microbiol; 2018 Nov; 56(11):. PubMed ID: 30209184
[TBL] [Abstract][Full Text] [Related]
6. Allplex HPV HR Detection assay fulfils all clinical performance and reproducibility validation requirements for primary cervical cancer screening.
Oštrbenk Valenčak A; Cuschieri K; Connor L; Zore A; Smrkolj Š; Poljak M
J Clin Virol; 2024 Feb; 170():105638. PubMed ID: 38183829
[TBL] [Abstract][Full Text] [Related]
7. Safety and acceptability of human papillomavirus testing of self-collected specimens: A methodologic study of the impact of collection devices and HPV assays on sensitivity for cervical cancer and high-grade lesions.
Leinonen MK; Schee K; Jonassen CM; Lie AK; Nystrand CF; Rangberg A; Furre IE; Johansson MJ; Tropé A; Sjøborg KD; Castle PE; Nygård M
J Clin Virol; 2018; 99-100():22-30. PubMed ID: 29289814
[TBL] [Abstract][Full Text] [Related]
8. Evidence regarding human papillomavirus testing in secondary prevention of cervical cancer.
Arbyn M; Ronco G; Anttila A; Meijer CJ; Poljak M; Ogilvie G; Koliopoulos G; Naucler P; Sankaranarayanan R; Peto J
Vaccine; 2012 Nov; 30 Suppl 5():F88-99. PubMed ID: 23199969
[TBL] [Abstract][Full Text] [Related]
9. Performance of a Cartridge-Based Assay for Detection of Clinically Significant Human Papillomavirus (HPV) Infection: Lessons from VALGENT (Validation of HPV Genotyping Tests).
Cuschieri K; Geraets D; Cuzick J; Cadman L; Moore C; Vanden Broeck D; Padalko E; Quint W; Arbyn M
J Clin Microbiol; 2016 Sep; 54(9):2337-42. PubMed ID: 27385707
[TBL] [Abstract][Full Text] [Related]
10. Anyplex II HPV28 detection and Anyplex II HPV HR detection assays are highly concordant with other commercial assays for detection of high-risk HPV genotypes in women with high grade cervical abnormalities.
Cornall AM; Poljak M; Garland SM; Phillips S; Tan JH; Machalek DA; Quinn MA; Tabrizi SN
Eur J Clin Microbiol Infect Dis; 2017 Mar; 36(3):545-551. PubMed ID: 27822653
[TBL] [Abstract][Full Text] [Related]
11. Diagnostic accuracy of cervical cancer screening and screening-triage strategies among women living with HIV-1 in Burkina Faso and South Africa: A cohort study.
Kelly HA; Chikandiwa A; Sawadogo B; Gilham C; Michelow P; Lompo OG; Omar T; Zan S; Magooa P; Segondy M; Nagot N; Meda N; Delany-Moretlwe S; Mayaud P;
PLoS Med; 2021 Mar; 18(3):e1003528. PubMed ID: 33661957
[TBL] [Abstract][Full Text] [Related]
12. Comparative evaluation of HPV genotyping: A study on the performance concordance between Anyplex II HPV28 detection and Linear Array genotyping tests in nationwide studies in Brazil.
Bandeira IC; Comerlato J; Bessel M; Fernandes BV; Mota G; Villa LL; de Souza FMA; Pereira GFM; Wendland EM
PLoS One; 2024; 19(6):e0305122. PubMed ID: 38861542
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of the Clinical Performance of the HPV-Risk Assay Using the VALGENT-3 Panel.
Polman NJ; Oštrbenk A; Xu L; Snijders PJF; Meijer CJLM; Poljak M; Heideman DAM; Arbyn M
J Clin Microbiol; 2017 Dec; 55(12):3544-3551. PubMed ID: 29021152
[TBL] [Abstract][Full Text] [Related]
14. Predominance of high-risk human papillomavirus genotype 16 and 39 in women with premalignant and malignant cervical pathology from Raipur, Chhattisgarh: Clinical evaluation of tagging oligonucleotide cleavage and extension mediated genotyping assay.
Negi SS; Bhargava A; Singh P; Aggarwal S; Hussain N; Das P
Indian J Med Microbiol; 2019; 37(2):255-262. PubMed ID: 31745028
[TBL] [Abstract][Full Text] [Related]
15. Aptima HPV Assay versus Hybrid Capture
Cook DA; Smith LW; Law J; Mei W; van Niekerk DJ; Ceballos K; Gondara L; Franco EL; Coldman AJ; Ogilvie GS; Jang D; Chernesky M; Krajden M
J Clin Virol; 2017 Feb; 87():23-29. PubMed ID: 27988420
[TBL] [Abstract][Full Text] [Related]
16. HPV genotype-specific distribution and attributable risk in cervical intraepithelial neoplasia in a referral population with a history of LSIL.
Ratnam S; Jang D; Alaghehbandan R; Gilbert L; Xu Y; Wang W; Andrews P; Green A; Speicher DJ; Chernesky M
Cancer Biomark; 2023; 38(4):433-442. PubMed ID: 37980645
[TBL] [Abstract][Full Text] [Related]
17. Comparison of Cobas® HPV and Anyplex™ II HPV28 assays for detecting and genotyping human papillomavirus.
Pasquier C; Sauné K; Raymond S; Boisneau J; Courtade M; Izopet J
Diagn Microbiol Infect Dis; 2017 Jan; 87(1):25-27. PubMed ID: 28336133
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of Human Papilloma Virus (HPV) Genotyping and Viral Load Determination as Diagnostic Biomarkers of Cervical Cancer Risk.
Martinelli M; Giubbi C; Saderi L; Musumeci R; Perdoni F; Leone BE; Fruscio R; Landoni F; Piana A; Sotgiu G; Cocuzza CE
Int J Mol Sci; 2023 Jan; 24(2):. PubMed ID: 36674835
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of the clinical performance of OncoPredict HPV® SCR assay within the VALGENT-2 framework.
Dhillon SK; Cocuzza CE; Chung PYJ; Martinelli M; Giubbi C; Njoku RC; Bhatia R; Cuschieri K; Arbyn M
J Med Virol; 2023 Jan; 95(1):e28417. PubMed ID: 36541733
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
